This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Katada, E. Articles by Ojika, K. Search for Related Content PubMed PubMed Citation Articles by Katada, E. Articles by Ojika, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Alzheimer's Disease Social Bookmarking                   What's this?

Long-Term Effects of Donepezil on P300 Auditory Event-Related Potentials in Patients with Alzheimer’s Disease

Department of Internal Medicine, Nagoya City Johoku Hospital, Japan

Koichi Sato, MD, PhD

Department of Internal Medicine, Nagoya City Johoku Hospital, Japan

Akira Sawaki, MD

Department of Internal Medicine, Nagoya City Johoku Hospital, Japan

Yasuaki Dohi, MD, PhD

Second Department of Internal Medicine, Nagoya City University Medical School, Japan

Ryuzo Ueda, MD, PhD

Second Department of Internal Medicine, Nagoya City University Medical School, Japan

Kosei Ojika, MD, PhD

Department of Neurology, Nagoya City University Medical School, Japan

The P300, one of the cognitive event-related potentials (ERPs) of the cerebral cortex, reflects the functioning of the neurochemical system involved in cognitive processes. We investigated clinical significance of the components of auditory P300 ERPs, in comparison with neuropsychologic tests including the Mini-Mental State Examination and the Japanese version of the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-J cog), for evaluating of the effect of donepezil (DPZ) (5 mg daily for 6 months), an acetylcholinesterase inhibitor, in patients with Alzheimer’s disease (AD). Reduction of P300 latency associated with a parallel improvement of ADAS-J cog scores was observed after administration of 5 mg/day of DPZ in patients with AD. P300 latency gives very useful information on the progression of AD, especially in the longitudinal follow-up of patients with AD during treatment with DPZ acting on cholinergic pathways. (J Geriatr Psychiatry Neurol 2003;16:39-43)

Key Words: Alzheimer’s disease • event-related potentials • auditory P300 • donepezil

Journal of Geriatric Psychiatry and Neurology, Vol. 16, No. 1, 39-43 (2003)
DOI: 10.1177/0891988702250561


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F. Chen, E. A. Eckman, and C. B. Eckman Reductions in levels of the Alzheimer's amyloid {beta} peptide after oral administration of ginsenosides FASEB J, June 1, 2006; 20(8): 1269 - 1271. [Abstract] [Full Text] [PDF]